Targeting urate to reduce oxidative stress in Parkinson disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Oxidative stress has been implicated as a core contributor to the initiation and progression of multiple neurological diseases. Genetic and environmental factors can produce oxidative stress through mitochondrial dysfunction leading to the degeneration of dopaminergic and other neurons underlying Parkinson disease (PD). Although clinical trials of antioxidants have thus far failed to demonstrate slowed progression of PD, oxidative stress remains a compelling target. Rather than prompting abandonment of antioxidant strategies, these failures have raised the bar for justifying drug and dosing selections and for improving study designs to test for disease modification by antioxidants. Urate, the main antioxidant found in plasma as well as the end product of purine metabolism in humans, has emerged as a promising potential neuroprotectant with advantages that distinguish it from previously tested antioxidant agents. Uniquely, higher urate levels in plasma or cerebrospinal fluid (CSF) have been linked to both a lower risk of developing PD and to a slower rate of its subsequent progression in numerous large prospective epidemiological and clinical cohorts. Laboratory evidence that urate confers neuroprotection in cellular and animal models of PD, possibly via the Nrf2 antioxidant response pathway, further strengthened its candidacy for rapid clinical translation. An early phase trial of the urate precursor inosine demonstrated its capacity to safely produce well tolerated, long-term elevation of plasma and CSF urate in early PD, supporting a phase 3 trial now underway to determine whether oral inosine dosed to elevate urate to concentrations predictive of favorable prognosis in PD slows clinical decline in people recently diagnosed, dopamine transporter-deficient PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 20×
“An early phase trial of the urate precursor inosine demonstrated its capacity to safely produce well tolerated, long-term elevation of plasma and CSF urate in early PD, supporting a phase 3 trial now underway to determine whether oral inosine dosed to elevate urate to concentrations predictive of favorable prognosis i…”
BackgroundInfluentialOxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · cited 1×
“Dopaminergic neurons are thought to be affected in PD due to their high intrinsic basal oxidative stress from both the enzymatic and nonenzymatic metabolism and autoxidation of dopamine, including through semiquinone formation and its polymerization (18,49-51).”
BackgroundEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 2×
“Vitamin E has been included in subsequent studies as a supplement in both coenzyme Q10 and its placebo (110,111).”
BackgroundZhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Oxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · cited 15×
“They also saw higher CSF urate in PD patients without dementia (median 0.7 mg/dl) compared to patients with Lewy body disorders and dementia (0.4 mg/dl; p = 0.03) (256).”
BackgroundInfluentialMitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Mitochondrial Defects and Oxidative Stress in Alzheimer Disease and Parkinson Disease
Yan, M. H., Wang, X., & Zhu, X. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.014 · Cited by 718 · cited 1×
“The electron transport chain is the major contributor of ROS at the mitochondrial level (12).”
BackgroundChen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid
Davies, K. J. A., Sevanian, A., Muakkassah-Kelly, S. F., & Hochstein, P. (1986) · Biochemical Journal · doi:10.1042/bj2350747 · Cited by 558 · cited 3×
“Hydrogen peroxide, in the presence of high iron levels in the SN, is also converted by Fenton reactions to the highly toxic hydroxyl radical, another free radical resulting in further oxidative damage (52,53).”
BackgroundProtein Nitration in Parkinsonʼs Disease
Good, P. F., Hsu, A., Werner, P., Perl, D. P., & Olanow, C. W. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00006 · Cited by 540
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Potential oxidative pathways of brain catecholamines
Tse, D. C. S., McCreery, R. L., & Adams, R. N. (1976) · Journal of Medicinal Chemistry · doi:10.1021/jm00223a008 · Cited by 415 · cited 1×
“Dopaminergic neurons are thought to be affected in PD due to their high intrinsic basal oxidative stress from both the enzymatic and nonenzymatic metabolism and autoxidation of dopamine, including through semiquinone formation and its polymerization (18,49-51).”
BackgroundBRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE
MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.2.333 · Cited by 346 · cited 2×
“Subsequent studies also found complex I deficiency in the platelets, lymphocytes and skeletal muscle tissues of patients with PD, although this was not consistently seen in skeletal muscle (28,57).”
BackgroundResultOxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300 · cited 3×
“Accepted Manuscript Targeting urate to reduce oxidative stress in Parkinson disease Grace F. Crotty, Alberto Ascherio, Michael A. Schwarzschild PII: S0014-4886(17)30157-7 DOI: doi: 10.1016/j.expneurol.2017.06.017 Reference: YEXNR 12558 To appear in: Experimental Neurology Received date: 27 April 2017 Revised date: ###…”
BackgroundInfluentialN-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases
Holmay, M. J., Terpstra, M., Coles, L. D., Mishra, U., Ahlskog, M., Öz, G., Cloyd, J. C., & Tuite, P. J. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31829ae713 · Cited by 216 · cited 1×
“Nacetylcysteine given orally or intravenously has been shown to increase GSH levels in the blood, brain and cerebrospinal fluid (117,118).”
BackgroundReduced intravenous glutathione in the treatment of early parkinson's disease
Sechi, G., Deledda, M. G., Bua, G., Satta, W. M., Deiana, G. A., Pes, G. M., & Rosati, G. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(96)00103-0 · Cited by 173
Risk factors for parkinson’s disease: The leisure world cohort study
Paganini-Hill, A. (2001) · Neuroepidemiology · doi:10.1159/000054770 · Cited by 159 · cited 1×
“In the Leisure World Cohort Study, in California, an increased risk of PD with dietary vitamin C and A intake was found in univariate analysis, but results were not significant in multivariate analysis (104).”
Cited by
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
New insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 364
Scioli, M. G., Storti, G., D’Amico, F., Rodríguez Guzmán, R., Centofanti, F., Doldo, E., Céspedes Miranda, E. M., & Orlandi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061995 · Cited by 281
“At physiological concentrations, uric acid reduces the oxo-heme oxidant, generated by the peroxide reaction with hemoglobin, protecting erythrocytes from peroxidative damage and lysis [125], and protects against oxidative damage by acting as an electron donor [126].”
BackgroundNutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
“UA has also metal-binding properties, preventing toxic effects of iron and copper on neurons [52].”
BackgroundZhao, H., Zhang, M., Liu, Q., Wang, X., Zhao, R., Geng, Y., Wong, T., Li, S., & Wang, X. (2018) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2018.1450201 · Cited by 14
Metadata
- Authors
- Crotty, G. F., Ascherio, A., & Schwarzschild, M. A.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 298
- Issue
- Pt B
- Pages
- 210-224
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2626775758
- Cited by
- 130
- References
- 23
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.